Henry I. Miller

Robert Wesson Fellow in Scientific Philosophy and Public Policy
Biography: 

Henry I. Miller, MS, MD, is the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution. His research focuses on public policy toward science and technology, encompassing a number of areas, including pharmaceutical development, genetic engineering in agriculture, models for regulatory reform, and the emergence of new viral diseases.

Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts. He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and thus instrumental in the rapid licensing of human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government. As a government official, Miller received numerous awards and citations.

Since coming to the Hoover Institution, Miller has become well known not only for his contributions to scholarly journals but also for his articles and books that make science, medicine, and technology accessible. His work has been widely published in many languages. Monographs include Policy Controversy in Biotechnology: An Insider's View; To America's Health: A Model for Reform of the Food and Drug Administration; and The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution. Barron's selected The Frankenfood Myth as one of the 25 Best Books of 2004. In addition, Miller has published extensively in a wide spectrum of scholarly journals and popular publications worldwide, including The Lancet, Journal of the American Medical Association, Science, the Nature family of journals, Chronicle of Higher Education, Forbes, National Review, Wall Street Journal, New York Times, the Guardian, Defining Ideas, and the Financial Times. He is a regulator contributor to Forbes.com and frequently appears on the nationally syndicated radio programs of John Batchelor and Lars Larson.

Miller was selected by the editors of Nature Biotechnology as one of the people who had made the "most significant contributions" to biotechnology during the previous decade. He serves on numerous editorial boards.

Filter By:

Topic

Type

Recent Commentary

Analysis and Commentary

Science Triumphs At The EPA. For Now.

by Henry I. Millervia Science 2.0
Thursday, May 17, 2018

In The Neonic Ban: A Scientific Fraud Becomes Enshrined In EU Regulatory Law, I described the many elements of corruption that led to Europe’s recently announced ban on neonic insecticides (“neonics”) which is based on the fallacy that they are responsible for a supposed collapse in bee populations. In fact, bee populations are rising on every habitable continent in the world, and have been since neonics first came on the market.

Analysis and Commentary

The Neonic Ban: A Scientific Fraud Becomes Enshrined In EU Regulatory Law

by Henry I. Millervia Science 2.0
Tuesday, May 15, 2018

Five years after the European Union imposed a temporary ban on neonicotinoid pesticides, an “experts committee” of the member states has now finally voted to make the ban permanent. This was hardly a surprise. The vote followed shortly after the European Food Safety Authority (EFSA) published their advisory opinion that neonics “represent a risk to wild bees and honeybees,” a finding that got banner headlines across Europe and the U.S.

Analysis and Commentary

Trump's New Prescription Drug Plan Is Incomplete -- Here Are Two Ways To Make It Better

by Henry I. Miller, John Cohrssenvia Fox News
Monday, May 14, 2018

On Friday President Trump in the White House Rose Garden briefly outlined the four key aspirational strategies of his "blueprint to lower drug prices": "improved competition, better negotiation, incentives for lower list prices, and lowering out-of-pocket costs."

Analysis and Commentary

To Solve Drug Prices, We Need More Competition, Not More Government Meddling

by Henry I. Miller, John Cohrssenvia Washington Examiner
Friday, May 11, 2018
President Trump has often criticized what he considers to be excessively high drug prices, castigating drug companies and accusing them of “getting away with murder.” He was scheduled to give a major speech on April 26 about initiatives intended to lower prescription drug prices, but it has been postponed until today.
Analysis and Commentary

Needed: An FDA Revolution

by Joseph V. Gulfo, Henry I. Millervia City Journal
Wednesday, May 2, 2018

To conquer crippling diseases like Alzheimer’s, the agency must change its whole approach to clinical drug trials.

Analysis and Commentary

The Benefits Of Genetically Modified Organisms

by Therese Liechtenstein , Henry I. Millervia GeoPolitical Intelligence Services
Friday, April 27, 2018

The issue of so-called “genetically modified organisms,” or GMOs, is frequently in the news and the subject of controversy. Perhaps pseudo-controversy is a better term, because much of the criticism is gratuitous and ill-informed.

Analysis and Commentary

Viewpoint: Examining The Science Denial Behind IFOAM—Organics International

by Henry I. Miller, Drew L. Kershenvia Genetic Literacy Project
Wednesday, April 25, 2018

The true-believers in organic agriculture, such as the International Federation of Organic Agriculture Movements (IFOAM—Organics International), are as deluded as those who deny the value of vaccines and, like them, have the potential to inflict tremendous harm.

Analysis and Commentary

Earth Day: More About Hurling Tomatoes Than Planting Them

by Henry I. Miller, Jeff Stiervia American Greatness
Tuesday, April 24, 2018

Earth Day has changed a lot since its inception in 1970, and not for the better. In the spirit of the time, it started as a touchy-feely, consciousness-raising, idealistic experience. Attendees were prototypic tree-huggers.

Blank Section (Placeholder)

Unscientific American

by Henry I. Millervia Hoover Digest
Friday, April 20, 2018

If we’re to withstand a torrent of unsound and biased research, we need to understand—and respect—scientific principles.

Analysis and Commentary

March For Science Was Just An Excuse To Attack Trump And Republicans

by Henry I. Miller, Alex Berezowvia Fox News
Friday, April 20, 2018

In Washington and cities around the country last weekend, events labeled The March for Science should have been labeled The March Against Trump. Few Republicans were invited and marchers carried signs that urged “Resist” and other anti-Trump slogans.

Pages